TrialInternational journal of clinical oncology2012

Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.

Shintaro Narita et al.PubMed ↗Publisher ↗

No numbers read from the abstract.